FOCUS: Mobile app support for taking oral cancer medicine
Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Qualitative Study: Utilization of an Adherence Application
This pilot tests whether the EveryDose mobile app helps adults starting an oral anti-cancer medication take their medicine as prescribed.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Trial ID | NCT06952790 on ClinicalTrials.gov |
What this trial studies
This is a single-center pilot using the EveryDose mobile application to track prescribed oral anti-cancer treatments and collect patient experiences. Adults with hematologic or solid tumor cancers who are beginning an oral anti-cancer drug for the first time will use the app and provide feedback during the treatment period. Study staff will review user-reported adherence, usability, and safety-related data to understand how the app fits into routine care. Findings will guide whether the team expands to larger evaluations or other supportive methods.
Who should consider this trial
Good fit: Adults (18+) with a hematologic or solid tumor cancer who are starting an oral anti-cancer drug for the first time, can read English or Spanish, can give written informed consent, and have internet access on a smartphone, tablet, or computer.
Not a fit: Patients under 18, those with prior oral anti-cancer treatment, dementia or major psychiatric illness that limits participation, inability to consent or read English/Spanish, or lack of internet-enabled devices are unlikely to benefit from this pilot.
Why it matters
Potential benefit: If successful, the app could improve adherence to oral cancer medications and reduce missed doses or medication errors.
How similar studies have performed: Similar medication-tracking and reminder apps have shown feasibility and modest improvements in adherence in small prior studies, but large randomized evidence in cancer patients is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any sex/gender Able to provide written informed consent * Able to read/understand English or Spanish * Diagnosis of hematologic or solid tumor cancer diagnosis * Prescribed an oral anti-cancer drug as monotherapy treatment for the first time by their treating oncologist. * Internet access on a smartphone, tablet, or computer Exclusion Criteria: * Less than 18 years of age * Unable to provide written informed consent * Unable to read/understand English or Spanish * History of dementia or major psychiatric disease that would interfere with study participation * Prior treatment with an oral anti-cancer treatment * Participating in another clinical trial during the time of screening.
Where this trial is running
Miami, Florida
- University of Miami — Miami, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Frank Penedo, PhD — University of Miami
- Study coordinator: Jessica MacIntyre, DNP
- Email: jmacintyre@med.miami.edu
- Phone: 305-243-4570
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.